JPH11500907A - 膵島新生に関与するingapタンパク質 - Google Patents
膵島新生に関与するingapタンパク質Info
- Publication number
- JPH11500907A JPH11500907A JP8525702A JP52570296A JPH11500907A JP H11500907 A JPH11500907 A JP H11500907A JP 8525702 A JP8525702 A JP 8525702A JP 52570296 A JP52570296 A JP 52570296A JP H11500907 A JPH11500907 A JP H11500907A
- Authority
- JP
- Japan
- Prior art keywords
- ingap
- mammalian
- protein
- mammal
- ingap protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101100189458 Mesocricetus auratus INGAP gene Proteins 0.000 title claims abstract description 61
- 230000009707 neogenesis Effects 0.000 title abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 111
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 64
- 239000000523 sample Substances 0.000 claims abstract description 43
- 239000002299 complementary DNA Substances 0.000 claims abstract description 31
- 210000000496 pancreas Anatomy 0.000 claims abstract description 24
- 229920000298 Cellophane Polymers 0.000 claims abstract description 14
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 11
- 230000035755 proliferation Effects 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 84
- 241000124008 Mammalia Species 0.000 claims description 67
- 108020004414 DNA Proteins 0.000 claims description 57
- 210000004153 islets of langerhan Anatomy 0.000 claims description 54
- 238000002360 preparation method Methods 0.000 claims description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 38
- 229920001184 polypeptide Polymers 0.000 claims description 35
- 150000001413 amino acids Chemical class 0.000 claims description 33
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 101150036490 INGAP gene Proteins 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 22
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 21
- 102000053602 DNA Human genes 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 20
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 16
- 210000000277 pancreatic duct Anatomy 0.000 claims description 15
- 108091034117 Oligonucleotide Proteins 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 206010012601 diabetes mellitus Diseases 0.000 claims description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- 230000000692 anti-sense effect Effects 0.000 claims description 8
- 235000015097 nutrients Nutrition 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 210000000130 stem cell Anatomy 0.000 claims description 7
- 230000009261 transgenic effect Effects 0.000 claims description 7
- 230000004071 biological effect Effects 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000009996 pancreatic endocrine effect Effects 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims description 6
- 208000035467 Pancreatic insufficiency Diseases 0.000 claims description 5
- 230000010261 cell growth Effects 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 5
- 238000003752 polymerase chain reaction Methods 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 239000004417 polycarbonate Substances 0.000 claims description 4
- 229920000515 polycarbonate Polymers 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 210000003240 portal vein Anatomy 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 241000282552 Chlorocebus aethiops Species 0.000 claims description 2
- 210000004381 amniotic fluid Anatomy 0.000 claims description 2
- 210000002459 blastocyst Anatomy 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 230000003833 cell viability Effects 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 239000002609 medium Substances 0.000 claims 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000001136 chorion Anatomy 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 238000010079 rubber tapping Methods 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 241000699800 Cricetinae Species 0.000 abstract description 18
- 230000024245 cell differentiation Effects 0.000 abstract description 2
- 210000003890 endocrine cell Anatomy 0.000 abstract description 2
- 210000001755 duct epithelial cell Anatomy 0.000 abstract 1
- 101000610097 Mesocricetus auratus Pancreatic beta cell growth factor Proteins 0.000 description 136
- 235000018102 proteins Nutrition 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 18
- 239000012634 fragment Substances 0.000 description 9
- 206010033645 Pancreatitis Diseases 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 150000005846 sugar alcohols Chemical class 0.000 description 5
- 239000004382 Amylase Substances 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- 240000002329 Inga feuillei Species 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108090000342 C-Type Lectins Proteins 0.000 description 3
- 102000003930 C-Type Lectins Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000581815 Homo sapiens Regenerating islet-derived protein 3-alpha Proteins 0.000 description 3
- 108010014691 Lithostathine Proteins 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 102000049256 human REG3A Human genes 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 206010022498 insulinoma Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 208000021255 pancreatic insulinoma Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108010027920 GTPase-Activating Proteins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000016997 Lithostathine Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 108700007677 rat Reg1a Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000669 Annexin A4 Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 101001035654 Homo sapiens 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 description 1
- 101000676246 Homo sapiens 60S ribosomal protein L29 Proteins 0.000 description 1
- 101000785915 Homo sapiens Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 Proteins 0.000 description 1
- 101001021500 Homo sapiens Hedgehog-interacting protein Proteins 0.000 description 1
- 101000735427 Homo sapiens Poly(A) RNA polymerase, mitochondrial Proteins 0.000 description 1
- 101100240462 Homo sapiens RASAL2 gene Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102100027361 Lithostathine-1-alpha Human genes 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000000713 Nesidioblastosis Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101150084044 P gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100031108 Pyroglutamyl-peptidase 1 Human genes 0.000 description 1
- 102100035410 Ras GTPase-activating protein nGAP Human genes 0.000 description 1
- 101000924464 Rattus norvegicus Annexin A3 Proteins 0.000 description 1
- 101000780140 Rattus norvegicus Annexin A5 Proteins 0.000 description 1
- 101001129571 Rattus norvegicus Pyroglutamyl-peptidase 1 Proteins 0.000 description 1
- 101000634877 Rattus norvegicus Thyrotropin-releasing hormone-degrading ectoenzyme Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102100028088 Thyrotropin-releasing hormone-degrading ectoenzyme Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- VPNMENGBDCZKOE-LNYNQXPHSA-N [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate [(1S,2S,4R,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate (1R,3S)-1,2,2-trimethylcyclopentane-1,3-dicarboxylic acid Chemical compound CC1(C)[C@H](CC[C@@]1(C)C(O)=O)C(O)=O.CC1(C)[C@H](CC[C@@]1(C)C(O)=O)C(O)=O.CN1[C@H]2CC[C@@H]1CC(C2)OC(=O)C(CO)c1ccccc1.CN1[C@H]2CC(C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 VPNMENGBDCZKOE-LNYNQXPHSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 101150097076 ngap gene Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/474—Pancreatic thread protein; Reg protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4733—Acute pancreatitis-associated protein
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.他の哺乳動物蛋白質を実質上含まない、哺乳動物INGAP蛋白質の調製物。 2.INGAP蛋白質が配列番号2に示されるアミノ酸配列を有する、請求項1記 載の調製物。 3.哺乳動物INGAP蛋白質の少なくとも15の連続するアミノ酸配列を含むポ リペプチド調製物。 4.ポリペプチドが上記配列と第2蛋白質由来の第2ポリペプチドとの融合物 である、請求項3記載の調製物。 5.ポリペプチドが第2ポリペプチドに結合している、請求項3記載の調製物 。 6.ポリペプチドが固相支持体に結合している、請求項3記載の調製物。 7.ポリペプチドが哺乳動物INGAP蛋白質の生物活性を有する、請求項3記載 の調製物。 8.生物活性が膵管細胞の成長および増殖を刺激する能力である、請求項7記 載の調製物。 9.ポリペプチドが配列番号2に示される哺乳動物INGAP蛋白質のアミノ酸番 号103番から122番を含む、請求項3記載の調製物。 10.ポリペプチドが哺乳動物INGAP蛋白質の少なくとも130の連続するア ミノ酸を含む、請求項3記載の調製物。 11.哺乳動物INGAP蛋白質をコードする、単離されたDNA分子。 12.INGAP蛋白質が配列番号2に示されるアミノ酸配列を有する、請求項1 1記載のDNA分子。 13.INGAP蛋白質が配列番号1に示されるアミノ酸配列を有する、請求項1 1記載のDNA分子。 14.請求項11記載のDNAを含むベクター。 15.さらに発現制御配列を含むことによりDNAが宿主細胞中で発現される 、請求項14記載のベクター。 16.EBNA Hisプラスミドを含む、請求項15記載のベクター。 17.請求項11記載のDNAで形質転換された宿主細胞。 18.請求項14記載のベクターで形質転換された宿主細胞。 19.アフリカミドリザルの腎臓細胞cos7である、請求項17記載の宿主 細胞。 20.以下の工程: セロファンラッピングにより哺乳動物膵臓細胞がINGAP蛋白質を発現するよう に誘導し;そして 誘導された哺乳動物膵臓細胞からINGAP蛋白質を精製すること により製造された、哺乳動物INGAP蛋白質の調製物。 21.哺乳動物INGAP遺伝子の少なくとも20の連続するヌクレオチドを含む ヌクレオチドプローブ。 22.哺乳動物INGAP遺伝子が配列番号1に示された配列を有する、請求項2 1記載のヌクレオチドプローブ。 23.プローブが検出可能なモイエティにより標識されている、請求項21記 載のヌクレオチドプローブ。 24.哺乳動物INGAP遺伝子の少なくとも20の連続するヌクレオチドを含む DNA分子。 25.哺乳動物INGAP遺伝子が配列番号1に示された配列を有する、請求項2 4記載のDNA分子。 26.検出可能なモイエティにより標識されている、請求項24記載のDNA 分子。 27.他の哺乳動物蛋白質を実質上含まない、哺乳動物の膵臓のセロファンラ ッピングにより誘導可能な哺乳動物INGAP蛋白質の調製物。 28.配列番号1に示される配列の少なくとも10の連続するヌクレオチドを 含むひとつまたはそれ以上のオリゴヌクレオチドを哺乳動物のゲノミックDNA またはcDNAにハイブリダイズさせて、 ひとつまたはそれ以上のオリゴヌクレオチドにハイブリダイズするゲノミック DNAまたはcDNAからDNA分子を同定すること からなる、哺乳動物からINGAP遺伝子を単離する方法。 29.2つのオリゴヌクレオチドをゲノミックDNAまたはcDNAにハイブ リダイズさせ、且つこれらのオリゴヌクレオチドをポリメラーゼチェイン反応( PCR)のプライマーとして用いることにより哺乳動物からINGAPヌクレオチド を合成する、請求項28記載の方法。 30.ひとつまたはそれ以上のオリゴヌクレオチドが標識されている、請求項 28記載の方法。 31.ハイブリダイズ工程において使用される哺乳動物のゲノミックDNAま たはcDNAが分子クローンのライブラリーの形態である、請求項28記載の方 法。 32.配列番号1に示される配列の少なくとも10の連続するヌクレオチドを 含むひとつまたはそれ以上のオリゴヌクレオチドを哺乳動物のゲノミックDNA またはcDNAにハイブリダイズさせて、 ひとつまたはそれ以上のオリゴヌクレオチドにハイブリダイズするゲノミック DNAまたはcDNAからDNA分子を同定する 方法により得られた、単離されたcDNA分子。 33.哺乳動物INGAP蛋白質に特異的に免疫反応する抗体調製物。 34.哺乳動物INGAPが配列番号2に示されるアミノ酸配列を有する、請求項 33記載の抗体調製物。 35.ポリクローナルである、請求項33記載の抗体調製物。 36.モノクローナルである、請求項33記載の抗体調製物。 37.固相支持体に結合した抗体を含む、請求項33記載の抗体調製物。 38.哺乳動物INGAP蛋白質に特異的に免疫反応する抗体を生成するハイブリ ドーマ。 39.以下の工程: 請求項17記載の宿主細胞を用意し; 宿主細胞を栄養培地中で培養してINGAP蛋白質を発現させ;そして、 宿主細胞または培地からINGAP蛋白質を回収すること からなる、哺乳動物INGAP蛋白質の製造方法。 40.以下の工程: 請求項11記載のDNA分子を含む宿主細胞を用意し; 宿主細胞を栄養培地中で培養して哺乳動物INGAP蛋白質を発現させ;そして、 宿主細胞または培地から哺乳動物INGAP蛋白質を回収すること からなる、哺乳動物INGAP蛋白質の製造方法。 41.治療に効果的な量のINGAP蛋白質を糖尿病の哺乳動物に投与して膵島細 胞の成長を刺激することからなる、糖尿病の哺乳動物の治療方法。 42.哺乳動物がインスリン依存性の真性糖尿病である、請求項41記載の方 法。 43.哺乳動物がインスリン非依存性の真性糖尿病である、請求項41記載の 方法。 44.INGAP蛋白質を膵島細胞増殖用培地に供給し;そして INGAP蛋白質を含有する培地中で膵島細胞を成長させること からなる、膵島細胞の成長方法。 45.膵島細胞の生存率または生存時間を高めるのに十分な量のINGAP蛋白質 を、ポリカーボンの殻で封入された膵島細胞に加えることからなる、ポリカーボ ンの殻で封入された膵島細胞の寿命を高める方法。 46.哺乳動物の膵臓にINGAP蛋白質をコードするDNA分子を投与すること からなる、哺乳動物の膵島細胞の数を増やす方法。 47.DNA分子が配列番号1に示される配列を有する、請求項46記載の方 法。 48.INGAP蛋白質が配列番号2に示されるアミノ酸配列を有する、請求項4 6記載の方法。 49.哺乳動物の膵臓にINGAP蛋白質を投与することからなる、哺乳動物の膵 島細胞の数を増やす方法。 50.INGAP蛋白質が配列番号2に示されるアミノ酸配列を有する、請求項4 9記載の方法。 51.第2の哺乳動物のINGAP遺伝子を含むトランスジェニック哺乳動物 。 52.該INGAP遺伝子が配列番号1に示される配列である、請求項51記 載のトランスジェニック哺乳動物。 53.該INGAP遺伝子が、当該哺乳動物のどの内在性INGAP遺伝子よ りも高い水準で発現される、請求項51記載のトランスジェニック哺乳動物。 54.遺伝子工学的に操作され、当該哺乳動物のINGAP遺伝子の挿入、欠 失を含むヒト以外の哺乳動物。 55.個々の哺乳動物のサンプルINGAP遺伝子における突然変異を同定し 、該突然変異がその遺伝子によってコードされたINGAP蛋白における構造上 の異常を起こすか、又はINGAP遺伝子の消失(デミニッシュド又はオブリタ レーテッド)発現を導く調節欠損を生じるものである、糖尿病の危険がある個々 の哺乳動物の同定方法。 56.該サンプルが血液サンプルである請求項55記載の方法。 57.該サンプルが羊水サンプルである請求項55記載の方法。 58.該サンプルが絨毛膜サンプルである請求項55記載の方法。 59.該サンプルが胚盤胞サンプルである請求項55記載の方法。 60.該サンプルが膵細胞サンプルである請求項55記載の方法。 61.前記サンプルを請求項33による抗体製剤を接触させることから成る、 哺乳動物からのサンプル中のINGAP蛋白を同定する方法。 62.哺乳動物INGAP蛋白の少なくとも15個の連続したアミノ酸からな る所定量のポリペプチドも前記サンプルと接触させる、請求項61記載の方法。 63.該ポリペプチドが検出可能に標識されている、請求項62記載の方法。 64.前記抗体製剤が固体支持体に固定されている抗体からなる、請求項61 記載の方法。 65.前記抗体製剤が固体支持体に固定されている抗体からなる、請求項62 記載の方法。 66.前記固体支持体に固定されていない標識ポリペプチドを検出する工程を 含む、請求項65記載の方法。 67.単離した哺乳動物の膵島細胞を、他の哺乳動物蛋白から実質上精製され た、哺乳動物INGAP蛋白の製剤と、該膵島細胞の生存率を増加させる量で、 接触させることから成る、前記細胞のアポトーシスを避けるために、哺乳動物の 膵島細胞を処理する方法。 68.哺乳動物INGAP蛋白を、膵島細胞の移植を受けた哺乳動物に投与し 、該投与が移植の前、間、又は後に行われる、膵島の移植を受けた哺乳動物の処 置方法。 69.前記投与工程が静脈内である、請求項68記載の方法。 70.前記投与工程が前記移植の局所に対する局所潅流で行う、請求項68記 載の方法。 71.前記投与工程が門静脈投与である請求項71記載の方法。 72.膵島細胞を門静脈から連続移植する、請求項71記載の方法。 73.β細胞前駆細胞から成る膵管細胞の培養物を、実質上他の哺乳動物蛋白 を含まない哺乳動物INGAP蛋白製剤と接触させることから成る、β細胞の前 駆細胞の分化を誘導する方法。 74.膵臓内分泌不全の哺乳動物から単離されたβ細胞前駆細胞からなる膵管 細胞製剤を、実質上他の哺乳動物蛋白を含まない哺乳動物INGAP蛋白の製剤 と接触させ;ついで この哺乳動物に、上記のように処置された膵管細胞を、自家移植することから 成る、膵臓内分泌不全の哺乳動物の治療方法。 75.プロモーター、ターミネーター、及び哺乳動物INGAP遺伝子から成 るヌクレオチド配列から成り、該ヌクレオチド配列が、該プロモーターとターミ ネータとの間に有り、該ヌクレオチドが、該プロモーターに対して逆方向であり 、それによって、該プロモーターからの発現の際に、ネイティブ哺乳動物ING APmRNAに相補的なmRNAを生産する、ことからなる哺乳動物INGAP 遺伝子のアンチセンス構造体。 76.膵島細胞症の哺乳動物に請求項75のアンチセンス構造体を投与し、そ れによって該哺乳動物のβ細胞の過度の成長を防止する、ことから成る膵島細胞 症の治療方法。 77.哺乳動物からのサンプル内の哺乳動物INGAP蛋白を検出するための キットであって、 哺乳動物INGAP蛋白と特異的に免疫反応性である抗体製剤;及び 哺乳動物INGAP蛋白の少なくとも15個の連続したアミノ酸からなるポリ ペプチドから成る、キット。 78.前記ポリペプチドが検出可能に標識されている、請求項77記載のキッ ト。 79.前記抗体製剤が、固体支持体に固定されている抗体からなる、請求項7 7記載のキット。 80.薬学上許容される希釈剤又は担体中に配合された、哺乳動物INGAP 蛋白から成る、膵臓不全の治療のための医薬組成物。 81.INGAP蛋白が、配列番号2に示されるアミノ酸配列である、請求項 80記載の医薬組成物。 82.哺乳動物INGAP蛋白の少なくとも15個の連続したアミノ酸からな るポリペプチド製剤と薬学上許容される希釈剤又は担体とからなる、医薬組成物 。 83.前記ポリペプチドが、第2の蛋白から誘導される第2のポリペプチドと 前記配列との融合物である、請求項82記載の医薬組成物。 84.前記ポリペプチドが、第2のポリペプチドと複合している、請求項82 記載の医薬組成物。 85.前記ポリペプチドが、前記哺乳動物INGAP蛋白の生物活性をもって いる、請求項82記載の医薬組成物。 86.前記生物活性が膵管細胞の成長、増殖を刺激する能力である、請求項8 5記載の医薬組成物。 87.前記ポリペプチドが配列番号2に示される哺乳動物INGAP蛋白にお ける103〜122アミノ酸である、請求項82記載の医薬組成物。 88.前記ポリペプチドが前記哺乳動物INGAP蛋白の少なくとも130個 の連続するアミノ酸からなる、請求項82記載の医薬組成物。 89.膵管細胞の集団を哺乳動物INGAP蛋白の製剤と接触させ;次いで 該集団から、INGAP蛋白に特異的に結合する細胞を検出する、ことから成 るβ細胞前駆細胞を同定する方法。 90.前記INGAP蛋白が検出可能に標識されている、請求項89記載の方 法。 91.前記INGAP蛋白が固体相上に固定化されている、請求項89記載の 方法。 92.INGAP蛋白がヒト由来のものであり、配列番号2に示される1〜8 3及び124〜174のアミノ酸配列から成る、請求項1記載の製剤。 93.INGAP蛋白がヒト由来のものであり、N末端からC末端への配向で 、配列番号2に示される1〜83、40アミノ酸、及び配列番号2の124〜1 74のアミノ酸配列から成る、請求項1記載の製剤。 94.INGAP蛋白がヒト由来のもである、請求項11記載のDNA分子。 95.前記INGAP蛋白が、配列番号2の1〜83及び124〜174のア ミノ酸配列である、請求項94のDNA分子。 96.INGAP蛋白がヒト由来のものであり、N末端からC末端への配向で 、配列番号2に示される1〜83、40アミノ酸、及び配列番号2の124〜1 74のアミノ酸配列から成る、請求項94記載のDNA分子。 97.配列番号2の1〜83及び124〜174のアミノ酸配列から選択され るアミノ酸配列をコードする、請求項24のDNA分子。 98.配列番号1の4〜268、及び389〜629のヌクレオチドから成る 、請求項11記載のDNA分子。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/401,530 US5834590A (en) | 1995-02-22 | 1995-02-22 | Ingap protein involved in pancreatic islet neogenesis |
US08/401,530 | 1995-02-22 | ||
US627195P | 1995-11-07 | 1995-11-07 | |
US60/006,271 | 1995-11-07 | ||
PCT/US1996/001528 WO1996026215A1 (en) | 1995-02-22 | 1996-02-12 | Ingap protein involved in pancreatic islet neogenesis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007124746A Division JP2007291114A (ja) | 1995-02-22 | 2007-05-09 | 膵島新生に関与するingapタンパク質 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11500907A true JPH11500907A (ja) | 1999-01-26 |
JP4111539B2 JP4111539B2 (ja) | 2008-07-02 |
Family
ID=26675411
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52570296A Expired - Fee Related JP4111539B2 (ja) | 1995-02-22 | 1996-02-12 | 膵島新生に関与するingapタンパク質 |
JP2007124746A Pending JP2007291114A (ja) | 1995-02-22 | 2007-05-09 | 膵島新生に関与するingapタンパク質 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007124746A Pending JP2007291114A (ja) | 1995-02-22 | 2007-05-09 | 膵島新生に関与するingapタンパク質 |
Country Status (6)
Country | Link |
---|---|
US (2) | US5840531A (ja) |
EP (1) | EP0815129B1 (ja) |
JP (2) | JP4111539B2 (ja) |
AT (1) | ATE494374T1 (ja) |
CA (1) | CA2213610C (ja) |
DE (1) | DE69638315D1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6265165B1 (en) * | 1998-11-12 | 2001-07-24 | The Regents Of The University Of California | Methods for EST-specific full length cDNA cloning |
US6986994B2 (en) * | 2001-01-09 | 2006-01-17 | Gmp Endotherapeutics, Inc. | INGAP displacement assays |
WO2002070551A2 (en) * | 2001-03-01 | 2002-09-12 | Mcgill University | Neuritogenic compound and uses thereof |
US6642003B2 (en) | 2001-08-02 | 2003-11-04 | Cedars-Sinai Medical Center | Human glucose-dependent insulin-secreting cell line |
US20040132644A1 (en) * | 2001-10-16 | 2004-07-08 | The Procter & Gamble Company | Composition and method for treating diabetes |
US7662768B2 (en) * | 2002-01-11 | 2010-02-16 | Mcgill University | Transdifferentiation of pancreatic acinar cells |
US7355024B2 (en) * | 2002-01-11 | 2008-04-08 | Gmp Endotherapeutics, Inc. | Regulatory sequences for modulation of INGAP expression and reporter constructs |
US7166439B2 (en) * | 2002-03-01 | 2007-01-23 | Gmp Endotherapeutics, Inc. | Assay for anti-INGAP antibodies |
US7141240B2 (en) * | 2002-03-12 | 2006-11-28 | Cedars-Sinai Medical Center | Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1 |
US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
US8211430B2 (en) * | 2005-03-04 | 2012-07-03 | Curedm Group Holdings, Llc | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
EP1883417A2 (en) * | 2005-05-25 | 2008-02-06 | Curedm Inc. | Peptides, derivatives and analogs thereof, and methods of using same |
US8785400B2 (en) * | 2006-11-22 | 2014-07-22 | Curedm Group Holdings, Llc | Methods and compositions relating to islet cell neogenesis |
KR20100080519A (ko) * | 2007-08-30 | 2010-07-08 | 큐어디엠 인코포레이티드 | 프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법 |
US8012928B2 (en) * | 2008-12-19 | 2011-09-06 | The Research Foundation Of State University Of New York | Truncated PAP2 and methods of making and using same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
FR2700011B1 (fr) * | 1992-12-24 | 1995-02-24 | Inst Nat Sante Rech Med | Détection de la mucoviscidose ou d'une mutation du gêne CFTR au moyen d'un dosage de la PAP. |
US5834590A (en) * | 1995-02-22 | 1998-11-10 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Ingap protein involved in pancreatic islet neogenesis |
-
1996
- 1996-02-12 EP EP96905368A patent/EP0815129B1/en not_active Expired - Lifetime
- 1996-02-12 CA CA2213610A patent/CA2213610C/en not_active Expired - Lifetime
- 1996-02-12 DE DE69638315T patent/DE69638315D1/de not_active Expired - Lifetime
- 1996-02-12 JP JP52570296A patent/JP4111539B2/ja not_active Expired - Fee Related
- 1996-02-12 AT AT96905368T patent/ATE494374T1/de not_active IP Right Cessation
- 1996-09-09 US US08/709,662 patent/US5840531A/en not_active Expired - Lifetime
-
2000
- 2000-11-22 US US09/717,095 patent/USRE39062E1/en not_active Expired - Lifetime
-
2007
- 2007-05-09 JP JP2007124746A patent/JP2007291114A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2007291114A (ja) | 2007-11-08 |
DE69638315D1 (de) | 2011-02-17 |
EP0815129A4 (en) | 2000-08-16 |
EP0815129B1 (en) | 2011-01-05 |
AU4914996A (en) | 1996-09-11 |
AU708499B2 (en) | 1999-08-05 |
ATE494374T1 (de) | 2011-01-15 |
EP0815129A1 (en) | 1998-01-07 |
US5840531A (en) | 1998-11-24 |
CA2213610A1 (en) | 1996-08-29 |
JP4111539B2 (ja) | 2008-07-02 |
MX9706418A (es) | 1998-07-31 |
USRE39062E1 (en) | 2006-04-11 |
CA2213610C (en) | 2013-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5834590A (en) | Ingap protein involved in pancreatic islet neogenesis | |
JP2007291114A (ja) | 膵島新生に関与するingapタンパク質 | |
JP2001512307A (ja) | プロエキセンジンをコードするポリヌクレオチドならびにその作製方法および使用 | |
JPH09509570A (ja) | Mts−1遺伝子により転移性癌の診断 | |
JP2002517977A (ja) | Tnfリガンドファミリーのntn−2メンバー | |
JP2002533058A (ja) | 97個のヒト分泌タンパク質 | |
JP2002526073A (ja) | 新規のヒト生長分化因子のコード配列、そのdna配列によりコードされるポリペプチド、およびこれらの製造方法。 | |
US7163795B2 (en) | Methods and compositions for pearl oyster cultivation | |
JP2001512667A (ja) | ヒトオーファンレセプターntr−1 | |
JPH0625295A (ja) | 新規生理活性物質エピモルフィン、それをコードする 遺伝子及びエピモルフィンに対する抗体 | |
WO2002053738A1 (fr) | Nouvelles proteines et adn correspondant | |
CN109971729B (zh) | 一种酶组合物 | |
JPH10512154A (ja) | 膵臓で発現する新規なケモカイン | |
JPH11514524A (ja) | リラキシンおよびリガンドのインスリンファミリーに関連する分子の分子クローニングおよび特徴付け | |
JPH11501817A (ja) | ヒト臍静脈内皮細胞で発現されるヒアルロン酸レセプタ | |
AU708499C (en) | Ingap protein involved in pancreatic islet neogenesis | |
CA2262412A1 (en) | Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof | |
JP2002504361A (ja) | 36個のヒト分泌タンパク質 | |
US6541251B1 (en) | Pancreatic progenitor 1 gene and its uses | |
EP1566386A1 (en) | A baldness related gene and the polypeptide encoded thereby, and uses thereof | |
JP2002538774A (ja) | Tiam2(t細胞のリンパ腫の侵襲およびmetastasis2)ヌクレオチド交換因子 | |
JP2001517444A (ja) | インスリン様ポリペプチドとその使用 | |
JP3799180B2 (ja) | ブタ血清レクチン遺伝子 | |
JP2001519180A (ja) | ラミニン及びそれらの利用 | |
JPH06293800A (ja) | 新規生理活性物質エピモルフィン、それをコードする 遺伝子及びエピモルフィンに対する抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040421 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070509 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070719 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070802 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071101 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080204 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080310 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080408 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110418 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |